In Blowout, Amarin ' s Fish-Oil-Derived Drug Dramatically Cuts Heart Risk In Study
The results, if they hold up, are likely to result in many patients getting the medicine, and could upend decades of orthodoxy among cardiologists.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:AMRN Source Type: news